Intelligent Bio Solutions Inc (INBS)
$2.36
+0.01
(+0.43%)▲
Insights on Intelligent Bio Solutions Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 764.06K → 823.8K (in $), with an average increase of 7.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -1.96M → -2.97M (in $), with an average decrease of 51.2% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 138.7%
Performance
- $2.27$2.42$2.36
3.81%
Downside
Day's Volatility :6.2%
Upside
2.48%
- $2.16$44.88$2.36
8.47%
Downside
52 Weeks Volatility :95.19%
Upside
94.74%
Returns
| Period | Intelligent Bio Solutions Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -57.63% | 0.0% |
6 Months | -39.3% | 0.0% |
1 Year | -93.62% | 0.0% |
3 Years | -97.91% | -22.6% |
Highlights
Market Capitalization | 7.3M |
Book Value | $3.82 |
Earnings Per Share (EPS) | -29.56 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -358.55% |
Return On Assets TTM | -45.62% |
Return On Equity TTM | -118.96% |
Revenue TTM | 2.8M |
Revenue Per Share TTM | 3.29 |
Quarterly Revenue Growth YOY | 80.2% |
Gross Profit TTM | 326.7K |
EBITDA | -9.3M |
Diluted Eps TTM | -29.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.67 |
EPS Estimate Next Year | -1.25 |
EPS Estimate Current Quarter | -0.87 |
EPS Estimate Next Quarter | -0.51 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 408.47%
Technicals Summary
Sell
Neutral
Buy
Intelligent Bio Solutions Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Intelligent Bio Solutions Inc | -4.84% | -39.3% | -93.62% | -97.91% | -97.91% |
 Stryker Corporation | 4.27% | 16.65% | 22.1% | 34.77% | 82.03% |
 Boston Scientific Corp. | 4.07% | 37.85% | 46.89% | 79.63% | 93.34% |
 Edwards Lifesciences Corp. | 3.26% | 27.0% | 2.23% | -8.36% | 51.45% |
 Abbott Laboratories | -2.62% | -2.21% | -0.86% | -5.87% | 32.8% |
 Medtronic Plc | 0.44% | 2.96% | -1.92% | -33.69% | -13.02% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Intelligent Bio Solutions Inc | 0.04 | NA | NA | -3.67 | -1.19 | -0.46 | NA | 3.82 |
Stryker Corporation | 38.89 | 38.89 | 2.92 | 11.96 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.5 | 63.5 | 1.8 | 2.33 | 0.09 | 0.05 | NA | 13.56 |
Edwards Lifesciences Corp. | 37.45 | 37.45 | 5.19 | 2.76 | 0.21 | 0.12 | NA | 11.82 |
Abbott Laboratories | 31.83 | 31.83 | 5.99 | 4.63 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 29.48 | 29.48 | 1.52 | 5.2 | 0.07 | 0.04 | 0.03 | 38.29 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Intelligent Bio Solutions Inc | Buy | $7.3M | -97.91% | 0.04 | 0.0% |
Stryker Corporation | Buy | $129.9B | 82.03% | 38.89 | 16.03% |
Boston Scientific Corp. | Buy | $111.1B | 93.34% | 63.5 | 12.05% |
Edwards Lifesciences Corp. | Buy | $52.4B | 51.45% | 37.45 | 23.01% |
Abbott Laboratories | Buy | $177.8B | 32.8% | 31.83 | 13.96% |
Medtronic Plc | Buy | $106.7B | -13.02% | 29.48 | 11.36% |
Institutional Holdings
Alyeska Investment Group, L.P.
7.08%Hudson Bay Capital Management LP
3.72%Vanguard Group Inc
0.53%Virtu Financial LLC
0.43%Citigroup Inc
0.27%
Company Information
Organization | Intelligent Bio Solutions Inc |
Employees | 51 |
CEO | Mr. Harry Simeonidis |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$2.36
+0.43%
Keyarch Acquisition Corp
$2.36
+0.43%
Connexa Sports Technologies Inc
$2.36
+0.43%
Us Value Etf
$2.36
+0.43%
First Wave Biopharma Inc
$2.36
+0.43%
Global X Msci Next Emerging
$2.36
+0.43%
Fat Projects Acquisition Corp
$2.36
+0.43%
Capital Link Global Fintech
$2.36
+0.43%
Applied Uv Inc
$2.36
+0.43%